3-Methyladenine (3-MA)

Catalog No.S2767 Synonyms: NSC 66389

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.

Size Price Stock Quantity  
USD 70 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 389 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Targets
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHFc5U{dU1? MnixNog> MkLQSG1UVw>? MnHldoVlfWOnczDndo94fGhiaX7obYJqfG:{eTDl[oZm[3Rib3[gRmROSw>? NVzEfpdKOjV5MU[1OlE>
A549  M4T3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHIdnBVO22P MVyybC=> NHPhe4lFVVOR MkK4doVlfWOnczDndo94fGhiaX7obYJqfG:{eTDl[oZm[3Rib3[gRmROSw>? NHW4RlYzPTdzNkW2NS=>
95D NWDTNZhUSXCxcITvd4l{KEG|c3H5 M3f2RVVuVQ>? NUXMNGUyOmh? Ml3JSG1UVw>? NHvsN25qdmirYnn0d{BDTE2FLXnu[JVk\WRiYYDvdJRwfGmlIHPlcIwh\GWjdHi= NETTeYIzPTdzNkW2NS=>
A549  MVzBdI9xfG:|aYOgRZN{[Xl? MYG1cW0> MlnZNog> MWTEUXNQ MYLpcohq[mm2czDCSG1ENWmwZIXj[YQh[XCxcITveIlkKGOnbHyg[IVifGh? MYqyOVcyPjV4MR?=
NBL-W-S  NV;6VmUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX1NY1O M{SxV|Zp NUXDU5Ix\W6qYX7j[ZMhT0GQVD22NUB1d3irY3n0fS=> MXGyOVMzOzJ{Mh?=
NBL-W-S  MYPBdI9xfG:|aYOgRZN{[Xl? MWKxcW0> MXW2bC=> Mk\qbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgS2FPXC14MR?= M{DWTlI2OzJ|MkKy
A2780cp  M2TCdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[xcW0> NXyzfGNVOWh? Mnv4bY5kemWjc3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> MlnINlU{OjJ4OUS=
A549  NV7UTI5ZTnWwY4Tpc44hSXO|YYm= NGT2[Ig2dU1? NVu3TYNoOmh? M1;WNJN2eHC{ZYPz[ZMhW1CFIHnu[JVk\WRiYXPjeY12dGG2aX;uJI9nKEyFMz3JTS=> NFeyNG0zPTJ6NU[yPC=>
H157 MoTJSpVv[3Srb36gRZN{[Xl? NXKwW4duPW2P NVO5bW1vOmh? MV7zeZBxemW|c3XzJHNRSyCrbnT1Z4VlKGGlY4XteYxifGmxbjDv[kBNSzNvSVm= NX3iTYZpOjV{OEW2Nlg>
MDR NFzrdpBCeG:ydH;zbZMhSXO|YYm= NF3O[WoyOG2P M2\JPFZp MoXRd5Rz\W6pdHjlcpMhfGinIIDve4VzKG:oIHHueIlk[W6lZYKg[JJ2\3N? MYeyOVAyQTdyMR?=
HT-29  MYnBdI9xfG:|aYOgRZN{[Xl? MlH6NY1O M1;3VVQ5cA>? M{DTVWROW09? NGfzOWxmdmijbnPld{Bjd3K2ZYrvcYljNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? MXyyOFg1OjF3OB?=
Microglia  Mn\DRZBweHSxc3nzJGF{e2G7 Mm\5OY1O M2jQbFI1cA>? MX;k[YNz\WG|ZYOgbJlxd3irYT3pcoR2[2WmIHPlcIwh\GWjdHi= NVzvUVJHOjR6MUi2NFE>
A2780cp M4\FeGFxd3C2b4Ppd{BCe3OjeR?= NFToVFMzNjWvTR?= MlToNYg> M4fRUYRlUDKR NWfLPVZR\W6qYX7j[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? NVvFUZg5OjR6MUe5OFY>
HepG2 MXfGeY5kfGmxbjDBd5NigQ>? NEe3PWw2dU1? M3\lOVRp NVTjbFBlcW6lcnXhd4V{KEiOIILlcIVie2V? MmHmNlQ4OTN3OEe=
A549 NVzmRoZMSXCxcITvd4l{KEG|c3H5 M{K3d|VuVQ>? NV\lXIN5PDiq MX7k[YNz\WG|ZYOgeIhmKHCncnPlcpRi\2Vib3[gZ4VtdCCmZXH0bEBidmRiZYjwdoV{e2mxbjDs[ZZmdHNib3[gZ4F{eGG|ZT2zMEBD\WOuaX6tNUBidmRiTFOzMWlK NVf2XJhGOjR5ME[zNFM>
U2OS MlvDRZBweHSxc3nzJGF{e2G7 MkjwNVBuVQ>? MmPBNlRp MVjpcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25ib3[geIhmKFV{T2OgZ4VtdHNiaX7keYNm\CCkeTDEc5g> NEC2O5gzPDZ|OUCxNy=>
Saos-2 Ml\aRZBweHSxc3nzJGF{e2G7 MUKxNI1O M1HRT|I1cA>? MUXpcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25ib3[geIhmKFV{T2OgZ4VtdHNiaX7keYNm\CCkeTDEc5g> M2P4U|I1PjN7MEGz
A549 Mk\PRZBweHSxc3nzJGF{e2G7 NHfQcocyOG2P MoDQOFhp Mm\nZYNk\WyncnH0[ZMhfGinIILl[JVkfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDpcoR2[2WmIHL5JHBVYA>? MYWyOFYzPjd{Mh?=
HCT116  MonYRZBweHSxc3nzJGF{e2G7 M1uxdlVuVQ>? NHzJcJUzPGh? NV75dWlP\W6qYX7j[ZMhfGinIHHwc5B1d3OrczDpcoR2[2WmIHL5JIFxcWenbnnu MXiyOFYzPjV{Mh?=
HGC-27 MWLGeY5kfGmxbjDBd5NigQ>? NGW0b2MyOG2P NYD4ZoxlOWh? NWDJZZlmcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGyxc4OgZpkhWkGGMECxJI9zKE2NLUKyNFY> MX2yOFQyPjN2OR?=
U2OS  M2f3emZ2dmO2aX;uJGF{e2G7 MmroNE42NzGvTR?= MV[0PIg> MUDpcoR2[2W|IIPhcIlvd227Y3nuMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> NX3jcoM4OjR|NUizOFI>
MG-63 NVe2enEyTnWwY4Tpc44hSXO|YYm= MmGxNE42NzGvTR?= NFXRbmQ1QGh? NGLpbldqdmS3Y3XzJJNidGmwb335Z4lvNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? MXKyOFM2QDN2Mh?=
MG-63 MYXBdI9xfG:|aYOgRZN{[Xl? M{i4RlAvPS9zbV2= NILSc4U{Omh? M3rMeIVvcGGwY3XzJJNidGmwb335Z4lvNWmwZIXj[YQh[2WubDDhdI9xfG:|aYO= NX7YT202OjR|NUizOFI>
MG-63 MWXBdI9xfG:|aYOgRZN{[Xl? MlzzNVBuVQ>? MnPUNVJp NXXGRlVG\W6qYX7j[ZMhTFBvaX7keYNm\CCjcH;weI9{cXN? NY\PSlFMOjR|NUizNFE>
NTUB1 NF\KXI9CeG:ydH;zbZMhSXO|YYm= NWjYfZZbPW2P MkPENU42cA>? M2\nd5BwfGWwdHnheIV{KGOnbHXjc5hq[i2rbnT1Z4VlKGGyb4D0c5Nqew>? NEPuZZAzPDN2OUG3Oi=>
T24 NIjydI9CeG:ydH;zbZMhSXO|YYm= MU[1cW0> NXzmcndNOS53aB?= MlfidI91\W62aXH0[ZMh[2WuZXPvfIljNWmwZIXj[YQh[XCxcITvd4l{ NWLoNW95OjR|NEmxO|Y>
SGC-7901  MmjvRZBweHSxc3nzJGF{e2G7 Moj1No1O NIX3PIQycA>? MUTpcoNz\WG|ZYOgR2EuPCCrbnT1Z4VlKGGyb4D0c5Nqew>? M3L3NVI1OzJzM{Sw
SMMC-7721 NEDqW3JCeG:ydH;zbZMhSXO|YYm= NUTNN3pQOm2P M{\SclFp MVLpcoNz\WG|ZYOgR2EuPCCrbnT1Z4VlKGGyb4D0c5Nqew>? M{fCWVI1OzJzM{Sw
ECSCs  M3vOTmFxd3C2b4Ppd{BCe3OjeR?= NYC5SHRnOTCvTR?= M3;t[|Rp MXLk[YNz\WG|ZYOgdoFx[W27Y3nuMZRz\WG2ZXSgZZBweHSxc3nz M1;QdlI1OzF7MUC5
MCF-7  NV:3T2VITnWwY4Tpc44hSXO|YYm= MXmxNI1O NWPNOYI5OjSq M{DoWYlvcGmkaYTzJJRp\SCjdYTvdIhi\3liaX7keYNm\CCkeTDjbIVud3SqZYLhdJkh\HK3Z4O= MWqyOFMyPTV5OB?=
UOK257 MkS0RZBweHSxc3nzJGF{e2G7 NXnucZNXPW2P MVGzbC=> MVLlcohidmOnczDwZYNtcXSjeHXsMY1m\GmjdHXkJIFxd3C2b4Ppd:Kh NYP4VFJTOjR|MEW2NFQ>
ACHN-5968 MXrBdI9xfG:|aYOgRZN{[Xl? M3nqZlVuVQ>? MUOzbC=> NFnTUnRmdmijbnPld{Bx[WOuaYThfIVtNW2nZHnheIVlKGGyb4D0c5Nqe8Li NGm5WowzPDNyNU[wOC=>
Huh7 NULiTXJPSXCxcITvd4l{KEG|c3H5 MYSycW0> M4TxcVEzcA>? NYDMXnlwTE2VTx?= MnrIbY5pcWKrdIOgRXpFQDB3NT3pcoR2[2WmIHPlcIwh\GWjdHi= Mo\UNlQzQTd|MEC=
Hep3B MXfBdI9xfG:|aYOgRZN{[Xl? Ml\TNo1O MnHGNVJp NYDXZlNMTE2VTx?= NELWdphqdmirYnn0d{BCYkR6MEW1MYlv\HWlZXSgZ4VtdCCmZXH0bC=> M2HQbVI1Ojl5M{Cw
RKO M2PBeGZ2dmO2aX;uJGF{e2G7 MUGycW0> NWH4SZkzOWh? MWXEUXNQ NWTmbY9X\W6qYX7j[ZMh[2WubDDk[YF1cCCkeTDn[Yxl[W6jbYnjbY4> MmHnNlQzQTF5N{e=
HepG2 E47 NXfFUmdYTnWwY4Tpc44hSXO|YYm= NIjweG8zNjWvTR?= NFvZTFc1QGh? MUDpcoNz\WG|ZYOgeIhmKHSxeHnjbZR6KG:oIFHBMEBDW09uIHHu[EBES2x2 MYOyOFI4Ozd|OB?=
LoVo  NXrDfFhCSXCxcITvd4l{KEG|c3H5 NUi3UYdoPW2P MmnCOFhp NYnOSGY5\W6qYX7j[ZMhTEODLXnu[JVk\WRiYYDvdJRwe2m|Lh?= NGXSN40zPDJyMUixNi=>
WiDr MUfGeY5kfGmxbjDBd5NigQ>? M3Gz[lExdU1? MV:xbC=> MYTpcohq[mm2czDQR2JNNWmwZIXj[YQhVEN|IFnJJIV5eHKnc4Ppc44> MYCyOFE6ODR6OR?=
H1299  MUjGeY5kfGmxbjDBd5NigQ>? M{LwSFExdU1? NEm5SmY1cA>? M2PpTIlv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp NYDuT2t2OjRzN{OyNFg>
H460 M{mwcWZ2dmO2aX;uJGF{e2G7 MmqwNVBuVQ>? NU\rPYl1PGh? M3LqbIlv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp M1jBSlI1OTd|MkC4
A549 MULGeY5kfGmxbjDBd5NigQ>? MVqxNI1O MmLCOIg> MlrwbY5pcWKrdIOgZZV1d3CqYXf5JIlv\HWlZXSgZpkhcXK{YXTpZZRqd25? MnPMNlQyPDJ5M{W=
Hep3B MYjBdI9xfG:|aYOgRZN{[Xl? NELVXpU2dU1? NIDDfXkzPGh? NXTOPFMy[XS2ZX71ZZRmeyCWTl[t{tEheHKxdHXjeIlwdiCjZ3HpcpN1KHOncoXtJJN1[XK4YYTpc44udWWmaXH0[YQh[XCxcITvd4l{ M4rTeFI1ODZ4Nkmz
SMMC-7721 NYrZeWsxSXCxcITvd4l{KEG|c3H5 MXS1cW0> Ml;5NlRp NH;3VmFifHSnboXheIV{KFSQRj5OtUBxem:2ZXP0bY9vKGGpYXnud5Qhe2W{dX2gd5Rien[jdHnvck1u\WSrYYTl[EBieG:ydH;zbZM> NVnMXYluOjRyNk[2PVM>
HO8910 NUC3boZQSXCxcITvd4l{KEG|c3H5 MXmxNI1O NXu3[2NvOTKq MVrlcohidmOnczDCNVkucW6mdXPl[EBieG:ydH;zbS=> NGfIblAzOzl6M{[xNC=>
MCF7 NUK5box{TnWwY4Tpc44hSXO|YYm= NYjB[XdTPW2P M3zteFI1cA>? NFrXSIdqdmO{ZXHz[ZMhS3WRIHnu[JVk\WRiY3XscEBl\WG2aB?= M4\J[|I{QTZ{NkK5
HONE-1  M1TET2Z2dmO2aX;uJGF{e2G7 MVO1cW0> NFfTUnMycA>? NHnNR21z\XC{ZYPz[ZMhPnJvbXXkbYF1\WRiUl;TJJBzd2S3Y4Tpc44> NUnqTYRDOjN6OUKzOVg>
HeLa NGLTPZlHfW6ldHnvckBCe3OjeR?= M3LuTFExdU1? NVXTTlc2Omh? NGL0SXR{fXCycnXzd4V{KEyFMzDJTUBmgHC{ZYPzbZNwdg>? MYiyN|g3PDd|OB?=
HepG2 NIfx[ZZHfW6ldHnvckBCe3OjeR?= MkXBNVBuVQ>? MnPNNlRp M2Xzb4lvcGmkaYTzJJNqXEmJQWKtJIFv\CCKQmPTMYlv\HWlZXSgZZV1d3CqYXf5 NY\0fIIxOjN6MUewOFA>
SH-SY5Y NETCO|FHfW6ldHnvckBCe3OjeR?= NF7ldFAydU1? NYH4ZppoOjSq NGD0cJJqdmirYnn0d{B1cGViYYX0c5Bp[We7IHnu[JVk\WRiYomgWG9EWA>? M4\tdlI{PzR|MUS4
SH-SY5Y M1n4eWFxd3C2b4Ppd{BCe3OjeR?= Mo\pOY1O M1X1OFFp MmjwZYJwdGm|aHXzJINmdGG|dILvcEBv\XW{b4Dyc5Rm[3SrdnWg[YZn\WO2 MV:yN|YyQTN7NR?=
PC12  NXvtN2cyTnWwY4Tpc44hSXO|YYm= NGnzUo0yOG2P NInNVFAzPGh? Ml3Se4F1\XJ? M3zIceKhcW6qaXLpeJMh[2i7bX;0dplxe2mwLXzpb4UheHKxdHXhd49u[WxiYXP0bZZqfHlw NYTjR5kxOjN4MEO5O|k>
OV2008 MmrKRZBweHSxc3nzJGF{e2G7 MljOOY1O MmT3NlRp M1S1OINwdn[ncoTzJGZVYTd{MDD3bZRpKEOGRGCgbY51dyCjbjDh[IRqfGm4ZTDl[oZm[3RidH;3ZZJleyCtaXzsbY5oKG:4YYLpZY4h[2GwY3XyJINmdGy| MkPuNlM2QTJ{OEG=
A2780 M2XKZWFxd3C2b4Ppd{BCe3OjeR?= NFm3dm02dU1? MnXhNlRp M{PzNoNwdn[ncoTzJGZVYTd{MDD3bZRpKEOGRGCgbY51dyCjbjDh[IRqfGm4ZTDl[oZm[3RidH;3ZZJleyCtaXzsbY5oKG:4YYLpZY4h[2GwY3XyJINmdGy| Mn\2NlM2QTJ{OEG=
Saos-2  NF\iSnFCeG:ydH;zbZMhSXO|YYm= MlvQNY1O M2\MXFk3cA>? M2CxbYlv[3KnYYPld{Bk\WyuIHTlZZRpKGmwZIXj[YQh[nliUFPY MYCyN|U3OzF5MR?=
1321N1 Mn7CR5l1d3SxeHnjbZR6KEG|c3H5 NHjPOFQ2dU1? NX;3RpVHOjSq NIDKdVZxem:2ZXP0d{Bk\WyuIHHnZYlve3RiUFPOMYlv\HWlZXSgeI95cWOrdIm= NIHGRZUzOzV{NUK2OS=>
SH-SY5Y M37hb2N6fG:2b4jpZ4l1gSCDc4PhfS=> NEPTT3o2dU1? MlvmNlRp NGKxc5JqdmO{ZXHz[ZMhWEOQIITvfIlkcXS7 NXjp[Y9zOjN3MkWyOlU>
HT-29  MULGeY5kfGmxbjDBd5NigQ>? M2nyPFFuVQ>? NXrPcldEPDhxOU\o Ml3wbY5pcWKrdIOgRW1RUyCrbnT1Z4V{KGG3dH;wbIFocWNiY3XscEBl\WG2aB?= MV:yN|UxQDJ5Mh?=
OR6 MneySpVv[3Srb36gRZN{[Xl? MlTmNVBuVQ>? NWLMVndiPzKq MUnzeZBxemW|c3XzJGhEXiC{ZYDsbYNifGmxbjDhcoQh\m:{bXH0bY9vKG:oIHH1eI9xcGGpb4PvcYV{ M2e3V|I{Ozl3OEe1
Hela  MYnGeY5kfGmxbjDBd5NigQ>? MlrIOY1O MYGyOIg> MUXpcohq[mm2czDzeIFzfmG2aX;uMYlv\HWlZXSgZZV1d3CqYXf5 MojGNlM{QTV4N{m=
MCF-7  NVnLOJNYTnWwY4Tpc44hSXO|YYm= M1fR[VVuVQ>? NHnj[20zPGh? NV[5XlZYcW6qaXLpeJMhe3Sjco\heIlwdi2rbnT1Z4VlKGG3dH;wbIFogQ>? NGDOcGczOzN7NU[3PS=>
HUVECs MnzFSpVv[3Srb36gRZN{[Xl? MXSzcW0> NYjJWmJCOjSq NWTib4xu[myxY3vzJJRp\SCycn;0[YN1cX[nIHXm[oVkfCCxZjDy[ZN3\XKjdILvcEBjgSCrbnjpZol1cW6pIHH1eI9xcGGpeR?= MVmyN|M2QDl{OB?=
T24 NEHvNnZHfW6ldHnvckBCe3OjeR?= M1rrc|ExdU1? NV\yXGVbOWh? NITr[Hpz\WS3Y3XzJJRp\SClbHXheoFo\SCxZjDMR|Mh[W[2ZYKgZoFq[2GuaX6geJJm[XSvZX70 NVKxbWZbOjN|NUSwPFA>
U251MG  NEnLTmRHfW6ldHnvckBCe3OjeR?= NUDkSJQ{O22P M1fPOlFp Mn\Md5VxeHKnc4Pld{BNSzNvSVmgdJJwfGWrbjDlfJBz\XO|aX;u NWLYN|lwOjN|M{i2NVg>
GTL-16  NXH2fZFMSXCxcITvd4l{KEG|c3H5 M3v6NlVuVQ>? MonrNlRp M1nocZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYYOgZ49ueGG{ZXSgeI8h[2WubIOgeJJm[XSnZDD3bZRpKE2HVDDpcohq[mm2b4Lz MW[yN|MyOzR7MB?=
T-47D MkHRSpVv[3Srb36gRZN{[Xl? MnHiNVBuVQ>? Ml\hNog> NXHWeJlRcW6qaXLpeJMh[XW2b4DoZYd6KHC{b3Pld5Mh[W6mIHnuZ5Jm[XOnczDyZZBidXmlaX6gbY5lfWOnZDDhdI9xfG:|aYO= NIq1bGEzOzNyMECyOi=>
PaCa44 MXjBdI9xfG:|aYOgRZN{[Xl? NVPPd2M4Oi53bV2= MWWxbC=> NYm2[FFCemWmdXPld:Kh\2WwaYDpck1u\WSrYYTl[EBieG:ydH;zbZM> MoTDNlMyOjRzMUK=
MDA-MB231 M1HGd2Z2dmO2aX;uJGF{e2G7 NFT6PYo2dU1? MnzyNYg> MnSwbY5kemWjc3XzJJJme3[ncnH0do9tNW2nZHnheIVlKGOjc4Dhd4Uh[WO2aY\heIlwdiCjbnSgZ4VtdCCmZXH0bC=> NFi4W5ozOzB6OEi1NC=>
HeLa MlTpRZBweHSxc3nzJGF{e2G7 NHnjVG4yOG2P MnfnNog> M3rVbYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDjc{11emWjdH3lcpQhf2m2aDDQSWk> NVW2WHJ3OjNyMECxN|U>
SK-HEP-1 NHfwe4pCeG:ydH;zbZMhSXO|YYm= MVyxNI1O MoHtNYg> NY\KfVkyeHKxdHXjeJMh[WejaX7zeEBifXSxcHjh[5kh[W6mIHnu[JVk\XNiYYDvdJRwe2m|IHnuJIJ2\mGuaX6teJJm[XSnZDDj[Yxtew>? M4nkVVIzQDV6NkS5
HepG2 M1fWV2Fxd3C2b4Ppd{BCe3OjeR?= M3rCOlNuVQ>? M2q3RVVp NFTXbmJz\WS3Y3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgVWR{ NV30NYo3OjJ6M{[1PVU>
MCF-7  NF2xSFZHfW6ldHnvckBCe3OjeR?= NVnRWnc{Om2P MlnhNlRp Ml3obY5pcWKrdIOgZZV1d3CqYXf5JIlv\HWlZXSgZpkhXE4EoB?= MViyOFk4ODZ5Nh?=
MDA-MB-231 MVPGeY5kfGmxbjDBd5NigQ>? MX6ycW0> MlH2NlRp Mn;zbY5pcWKrdIOgZZV1d3CqYXf5JIlv\HWlZXSgZpkhXE4EoB?= MXOyOFk4ODZ5Nh?=
MCF-7  NGTkb2tHfW6ldHnvckBCe3OjeR?= NHzDUVMzdU1? Mon6OFhp NYrRbFNpeHKxbX;0[ZMhXE1vaX7keYNm\CClZXzsJIRm[XSq MVWyOFk4ODZ5Nh?=
MDA-MB-231 NInyZ5RHfW6ldHnvckBCe3OjeR?= MnW5No1O MX60PIg> NFnrUWRxem:vb4Tld{BVVS2rbnT1Z4VlKGOnbHyg[IVifGh? NUnEWJJ7OjR7N{C2O|Y>
PANC-1  NWPpWHRLSXCxcITvd4l{KEG|c3H5 MlLrNY1O MkXCOFhp M2nGXmROW09? NIHLUmdmdmijbnPld{Bjd3K2ZYrvcYljNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? NUDOZWVvOjR6NEKxOVg>
MDA-MB 231 MXHBdI9xfG:|aYOgRZN{[Xl? MnvVOY1O NIrpc3MxNjWq Mn;3cY9lfWyjdHXzJHRw[2:vaX9CsuKhcW6mdXPl[EBieG:ydH;zbZM> NGj4O4kzPDh|MEe4NS=>
Microglia  NFXxbHVCeG:ydH;zbZMhSXO|YYm= NXjuflBPPW2P NEHUV4IzPGh? M1XGSIRm[3KnYYPld{BpgXCxeHnhMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MmTSNlQ5OTh4MEG=
A2780cp MmHWRZBweHSxc3nzJGF{e2G7 M3;iNlIvPW2P NXPnSXJbOWh? NYqzPWk4\GSKMl:= MVnlcohidmOnczDjbZNxdGG2aX6tbY5lfWOnZDDj[YxtKGSnYYTo MVuyOFgyPzl2Nh?=
HepG2 M3nCOWZ2dmO2aX;uJGF{e2G7 MWW1cW0> NYXRUm06PGh? NWruVHlMcW6lcnXhd4V{KGOnbHz1cIFzKGyndnXsd{Bw\iCKTNMg M2n2flI1PzF|NUi3
U2OS NGTEd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP0eFUyOG2P NGm0SGMzPGh? MkfXbY51\W6|aX\p[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIHnu[JVk\WRiYomgSI95 M2\Ee|I1PjN7MEGz
HCT116 MUXBdI9xfG:|aYOgRZN{[Xl? M33GfVVuVQ>? NXX5RYxsOjSq Mo\oSG1UVw>? MoH4[Y5p[W6lZYOgZZBq\2WwaX6tbY5lfWOnZDDj[YxtKGSnYYTo NX3wSIZLOjR4Mk[1NlI>
MCF-7  MXjBdI9xfG:|aYOgRZN{[Xl? NGe1W4ExNjGvTR?= MlXTOog> NHO2WphmdmijbnPld{B{cXK2aX7vcE1qdmS3Y3XkJIFxd3C2b4Ppdy=> MUiyNlc2OTl6OR?=
PC-3  MnnhRZBweHSxc3nzJGF{e2G7 MmeyNo1O NUe3RWpTOmh? MUjpcoNz\WG|ZYOgU3JKNWmwZIXj[YQh[2WubDDk[YF1cA>? M2[5blIzPzR3NUiw
U251  M4e4WGFxd3C2b4Ppd{BCe3OjeR?= NHe0Oo02dU1? M1TzelI1cA>? M1HZW4lv[3KnYYPld{BUOS2rbnT1Z4VlKGOnbHyg[IVifGh? M{niUlIzPTd7N{i4
HeLa  MmexRZBweHSxc3nzJGF{e2G7 Mn[xOY1O MnHtNlRp NIHLUFlqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JINmdGxiZHXheIg> NHXlU24zOjV2NUGyPC=>
A549 NWHnVW9{TnWwY4Tpc44hSXO|YYm= MnrXNE4ydU1? MX6yOIg> NIDBcop{fXCycnXzd4V{KFOXMUGyO|QucW6mdXPl[EBk\WyuIHTlZZRp MlfhNlI1PjZ7NkC=
pDCs NXnzZpNPTnWwY4Tpc44hSXO|YYm= NILnWZYyOG2P MUOwMlVp NHqxbXrDqHKnZIXj[ZMhfGinIHnu[JVkfGmxbjDv[kBKTk5vzsGgZpkhe3OUTlG0NC=> MnXtNlI{QTZ3OUm=
BGC-823 MkLQSpVv[3Srb36gRZN{[Xl? M{fhSlVuVQ>? M37pUFJp NIrpR5BqdmirYnn0d{B1cGVicnH0[UBw\iCjdYTvdIhi\2mlIHPlcIx{ MlfVNlI{OjJzNUK=
U937 NIfoOHlHfW6ldHnvckBCe3OjeR?= M2GxclJuVQ>? MYixNog> MmfO[IVkemWjc3XzJJRp\SCjdYTvdIhi\3licnH0bY/DqA>? MoLjNlIyPTVzNUC=
Marc-145 MmnhSpVv[3Srb36gRZN{[Xl? MUi1cW0> MXyxNk8zPC9|Nni= MnzJdoVlfWOnczD0bIUhWFKUU2[geIl1\XK|IHHu[EB1cGVicILveIVqdiCneIDy[ZN{cW:w MnPRNlIyOTl7MEC=
HBx  M2WxRWFxd3C2b4Ppd{BCe3OjeR?= Mlz1NVBuVQ>? MVy0PIg> NV\sNlJ6TE2VTx?= NVjobZdZcW6lcnXhd4V{KGOnbHyg[IVifGh? NFLpVm8zOjB{MEC3PC=>
MCF-7 Ml7MSpVv[3Srb36gRZN{[Xl? NXH6XmxNOTCvTR?= NWPr[25WPDiq NWHiTZhb[myxY3vzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KGKxcoTlfo9ucWJ? NGnkWGMzOTl|MUmzOy=>
RMPI8226  MY\GeY5kfGmxbjDBd5NigQ>? MkLuOY1O M1fvT|Fp M2rnVZN2eHC{ZYPz[ZMhfGinIHzleoVtKG:oIHH1eI9xcGGpeTD1coRmeiCwdYTybYVvfCCmZYDs[ZRqd25? NITsemIzOTlzNU[yNC=>
PC12/TetOn NYGyXJN3TnWwY4Tpc44hSXO|YYm= NEjJd3kxNjFxMX3N M{nsVlE5cA>? NEHSS2Nt\WGmczD0c{DPuS2|eX6oW3QqKGGlY4XteYxifGmxbjygeI95cWOrdImsJIFv\CCxbHnnc41meiCob4LtZZRqd28EoB?= NV7yTGxJOjF7ME[2OVk>
HeLa  M4LDVWN6fG:2b4jpZ4l1gSCDc4PhfS=> MmrSNo1O NF7RcIozPGh? MkDybY5pcWKrdHXzJJRp\SCleYTveI95cWOrdImgc4Yhe2muaXLpcolvKHSxIFjlUIEh[2WubIOu NIW3Z5gzOTh5NUO4OS=>
Jurkat M{[2fmZ2dmO2aX;uJGF{e2G7 MUGxNI1O NGXSZ3MycA>? MXnk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUGM{NUmLIHHu[EB1cGViZn;ycYF1cW:wIH;mJIF2fG:yaHHnc5NwdWW| MWeyNVg3PDB|Nx?=
K562 NHX5WnVHfW6ldHnvckBCe3OjeR?= MlewNVBuVQ>? MXSxbC=> MX3k[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUGM{NUmLIHHu[EB1cGViZn;ycYF1cW:wIH;mJIF2fG:yaHHnc5NwdWW| NXrEWodCOjF6NkSwN|c>
Nara-H MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Da[FVuVQ>? M2\jVFQ5cA>? MnjT[Y5p[W6lZYOgeIVue2m{b3zpcZV{dWWmaXH0[YQhe3WycILld5Nqd25ib3[gUoFz[S2KIHPlcIwheHKxbHnm[ZJifGmxbh?= MlH2NlE5ODVyM{O=
HUVECs MoS4SpVv[3Srb36gRZN{[Xl? MX[xNI1O NFv3VIIxNjWq MXnk[YNz\WG|ZYOgeIhmKEGJRT3CV2FqdmS3Y3XkJIF2fG:yaHHnfUBt\X[n NF23VoUzOTR4OEW5Ni=>
HepG2 NHzIV3BCeG:ydH;zbZMhSXO|YYm= NWLRVJlEOm2P M17SUVFp MXrlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDj[YxtKGSnYYTo M174PVIyPDV|Nkmx

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
α-SMA / TGF-β / LC-3BI / LC-3B II / Beclin-1 / NF-κB p65; 

PubMed: 29296191     


Western blotting analysed expression of α-SMA, TGF-β, LC-3B, Beclin-1, NF-κB and NF-κBp65 in hepatic stellate cells.

caspase-3 / caspase-9 / PARP; 

PubMed: 25891159     


EC9706 cell lysates were prepared and subjected to immunoblotting with antibodies against caspase-3, caspase-9 and PARP. The expression ratios in each experiment were determined densitometrically. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; PI, propidum iodide; PARP, poly(ADP ribose) polymerase.

VEGF; 

PubMed: 25891159     


Effects of autophagy inhibition on the protein expression levels of VEGF. Western blot analysis demonstrated that VEGF protein expression levels were decreased when the EC9706 human esophageal squamous cell carcinoma cells were treated with 3-MA. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; VEGF, vascular endothelial growth factor.

APP / BACE1 / ADAM17 / Presenilin 1 / Presenilin 2 / Nicastrin / APH-1 / Pen-2 / LC3-1 / LC3-2; 

PubMed: 26316755     


Presenilin 1, Nicastrin, and Pen-2 were increased with the 3-MA treatment (*P<0.001) while the other component of the γ-secretase complex (APH-1 and Presenilin 2) has no difference. 3-MA, 3-methyladenine; Con, control; APP, amyloid protein precursor.

29296191 25891159 26316755
Immunofluorescence
LC3 / Hif-α / COX2; 

PubMed: 29039446     


Chemical interventions of autophagy and ischemic-hypoxic injury, assessed using immunochemical double labeling. Compared with the control group, expression levels of HIF-α and COX2 were altered by chemical intervention. (A) Chemical intervention altered the expression of HIF-α and autophagosmes. Following autophagy antagonist (3-MA) intervention, expression of HIF-α was enhanced, compared with that in the OGD group, and was decreased by the autophagy agonist, rapamycin. In the MHY treatment group, expression of HIF-α was similar to that in the 3-MA group. (B) Chemical intervention showed changes in the expression of COX2 and autophagosomes. Changes in the expression of COX2 were similar to changes in HIF-α. Scale bar, 30 µm. OGD, oxygen-glucose deprivation; HIF-α, hypoxia-inducible factor-α; COX2, cyclooxygenase 2; 3-MA, 3-methyladenine; RP, rapamycin; MHY, MHY1485.

29039446
Growth inhibition assay
Cell viability; 

PubMed: 26934124     


KYSE 180 cells were co-treated with EDHB (40 μg/ml) and various concentrations of 3-MA for 24 h (left) or 48 h (right), and cell viability was determined by WST-8 assays.

26934124
In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]

Protocol

Kinase Assay:[4]
- Collapse

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:[2]
- Collapse
  • Cell lines: HeLa cell line
  • Concentrations: 1-10 mM
  • Incubation Time: 24, 48 or 72 hours
  • Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.
    (Only for Reference)
Animal Research:[5]
- Collapse
  • Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g
  • Formulation: Saline
  • Dosages: 400 nM
  • Administration: Intracerebral ventricular
    (Only for Reference)

Solubility (25°C)

In vitro Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 149.15
Formula

C6H7N5

CAS No. 5142-23-4
Storage powder
in solvent
Synonyms NSC 66389

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • Answer:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID